NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Tuesday that its revenue for the fourth quarter of 2014 is expected to be approximately $33.4 million.

On average, analysts were expecting Q4 revenues of $33.3 million for the South San Francisco, Calif.-based life science analytical and preparatory systems firm.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.